Accuray (ARAY) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
27 Dec, 2025Executive summary
Q3 FY25 net revenue increased 12% year-over-year to $113.2M, with net loss narrowing to $1.3M from $6.3M and Adjusted EBITDA rising to $6.0M from $1.1M, driven by higher shipments in APAC and China and service revenue growth.
27 systems delivered globally in Q3, a 23% increase year-over-year.
Operating expenses declined 9% year-over-year, reflecting cost controls and lower R&D and G&A spending.
Cash position improved to $79M, up $15M sequentially from the previous quarter.
China JV contributed $2.3M in equity income, up 124% year-over-year, supporting local sales growth.
Financial highlights
Q3 FY25 net revenue: $113.2M (+12% YoY); YTD: $331.0M (+6% YoY).
Product revenue: $57.3M (+16% YoY); service revenue: $55.9M (+9% YoY).
Gross margin for Q3 FY25 was 27.9%, down from 28.7% prior year; nine-month gross margin at 32.6%.
Q3 FY25 operating income was $1.0M, reversing a $4.6M loss in the prior year quarter.
Cash and equivalents at quarter-end: $77.8M–$79M, up $14.8M–$15M sequentially.
Outlook and guidance
FY25 revenue guidance revised to $452M–$460M due to tariff impacts; Adjusted EBITDA guidance reaffirmed at $28.5M–$31M.
Q4 revenue expected in the range of $121M–$129M; Q4 Adjusted EBITDA guidance is $9.5M–$12M.
Management expects sufficient liquidity for at least 12 months but highlights refinancing needs for $167M in debt maturing in 2026.
Mitigation efforts underway to offset tariff impacts, with greater positive effects expected in the second half of FY 2026.
Guidance for non-GAAP measures excludes depreciation, amortization, stock-based comp, interest, and taxes.
Latest events from Accuray
- Shelf registration covers resale of 7M shares from warrants tied to recent financing.ARAY
Registration Filing17 Feb 2026 - Revenue and margin guidance cut as China headwinds, tariffs, and financing changes weigh.ARAY
Q2 202617 Feb 2026 - Record Q4 revenue and robust FY25 outlook highlight strong growth and global expansion.ARAY
Q4 20241 Feb 2026 - Growth driven by innovation, emerging markets, and margin expansion, with U.S. recovery expected.ARAY
Jefferies Global Healthcare Conference31 Jan 2026 - FY2025 guidance raised as China growth and service gains offset margin and revenue declines.ARAY
Q1 202516 Jan 2026 - Q2 revenue up 8% to $116.2M, net income $2.5M, margin 36.1%, guidance raised.ARAY
Q2 202524 Dec 2025 - Resale registration covers 23.4M shares from warrant exercises tied to recent financing.ARAY
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, equity plan increases, pay, and auditor ratification.ARAY
Proxy Filing1 Dec 2025 - Major leadership changes and transformation plan target growth, margin expansion, and agility.ARAY
Proxy Filing1 Dec 2025